FeesSafety
Pluang+

SRM token's 2026 outlook hinges on Serum's role in DeFi infrastructure and order-book reuse.

Protocol Fundamentals
24 Oct 2026
Tokenpost
View Source
Neutral
SRM token's 2026 outlook hinges on Serum's role in DeFi infrastructure and order-book reuse.

The SRM token, linked to the decentralized exchange Serum, faces a critical price forecast for August 20, 2026. Its future value depends on whether Serum or its technology secures a significant role in decentralized finance (DeFi) infrastructure. Beyond 2026, the token's longer-term potential through 2030 is tied to the adoption of Serum's order-book model or assets by other DeFi platforms. This potential reuse is seen as a key factor for selective price gains in the future.

Serum's SRM token outlook is presented here with Pluang market data for context. For readers following cryptocurrency markets, 6 of 50 major cryptocurrencies rose while 43 fell as of Oct 24, 2026 18:51 WIB. Notable movers include EGLD at Rp60.783 with a 7.38% decline and 91% sell activity, ONE at Rp24 with a 7.12% decline and 97% buy activity, and COTI at Rp198 with a 6.11% decline and 84% sell activity.

More News

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
U.S. Bitcoin ETFs saw $6.4B inflows since August, outpacing corporate buys amid rising producer prices and rate hike bets.

U.S. Bitcoin ETFs saw $6.4B inflows since August, outpacing corporate buys amid rising producer prices and rate hike bets.

Since August, U.S. spot Bitcoin exchange-traded funds (ETFs) have attracted about $6.4 billion in net inflows, significantly more than the roughly $1.5 billion in Bitcoin purchases by corporate treasuries. BlackRock’s IBIT ETF led with around $6 bill...

Market News
Bullish
4 hours ago
Aave (AAVE) price drops 5.29% to $140.12, dipping below key technical support levels.

Aave (AAVE) price drops 5.29% to $140.12, dipping below key technical support levels.

Aave (AAVE) experienced a 5.29% decline over 24 hours, falling to $140.12 as of early Saturday. This price slipped 51 cents below the lower Bollinger Band level of $140.63, a technical indicator noted on October 22. The chart also showed a relative s...

Technical Signals
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App